14 March 2018 | News
Schleyer as Senior Vice President of Business Development, North America, and Christoph Winterhalter as Senior Vice President of Business Development, Europe
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced the appointment of Axel Schleyer as Senior Vice President of Business Development, North America, and Christoph Winterhalter as Senior Vice President of Business Development, Europe. Mr. Schleyer and Mr. Winterhalter will report to Robert Broeze, Chief Business Officer.
Mr. Schleyer brings more than 17 years of leadership experience in business development and key account management for pharmaceutical, biotechnology, and contract manufacturing organizations.
Along with his deep industry expertise, he holds a demonstrated track record of building and leading high-performance teams, spearheading international business development initiatives, and designing and implementing strategic business plans across the globe.
He most recently served as Vice President of Business Development - Americas & Asia/Pacific at Boehringer Ingelheim, where he was responsible for driving business efforts and strategic direction with an emphasis on the US and Asia, as well as establishing strong operational presence and strengthening international market awareness.
Mr. Winterhalter brings more than 20 years of business development leadership experience within Life Sciences organizations throughout Europe and the US.
He has a strong background in assembling and managing successful teams, and implementing strategic global business development plans within diverse and multicultural environments.
He most recently served as Senior Vice President at Rentschler Biotechnologie GmbH, where he was responsible for global strategy development and execution, development of new business models, account management, and cultivation of key alliances.
Under the AGC Biologics name, and with the support of Mr. Schleyer and Mr. Winterhalter, the company will maintain and grow its global presence with microbial and mammalian capabilities, fulfilling early-phase through commercial production, both at small and large-scale.